Association between matrix metalloprotease-3 levels and radiographic progression in patients with RA: a post hoc analysis from a Japanese phase 3 clinical trial of peficitinib (RAJ4).

Takeuchi, Tsutomu; Tanaka, Yoshiya; Morita, Yoshiaki; Kato, Daisuke; Kaneko, Yuichiro; Terada, Wataru

Takeuchi, Tsutomu; Tanaka, Yoshiya; Morita, Yoshiaki; Kato, Daisuke; Kaneko, Yuichiro; Terada, Wataru.

Afiliação

Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Tanaka Y; Saitama Medical University, Saitama, Japan.
Morita Y; The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
Kato D; Medical Affairs Japan, Astellas Pharma Inc., Tokyo, Japan.
Kaneko Y; Sustainability Department, Astellas Pharma Inc., Tokyo, Japan.
Terada W; Statistical & RWD Science Group, Data Science, Astellas Pharma Global Development Inc., IL, USA.

Mod Rheumatol ; 2023 Oct 30.

Article em En | MEDLINE | ID: mdl-37902304

Palavras-chave

biomarker; matrix metalloprotease-3; peficitinib; radiographic progression; rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article